Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density
(2MD-3H-2B Trial)
Recruiting in Palo Alto (17 mi)
+8 other locations
Age: 18+
Sex: Female
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Deltanoid Pharmaceuticals
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This study will evaluate the effect of a 1-year administration of the vitamin D analog 2-methylene-19-nor-(20S)-1alpha, 25-dihydroxyvitamin D3 (DP001) on bone mineral density (BMD), safety, and tolerability.
Research Team
WA
Wendy A Bedale, Ph.D.
Principal Investigator
Deltanoid Pharmaceuticals
Eligibility Criteria
Inclusion Criteria
Postmenopausal female subjects, defined as amenorrheic for at least 5 years
Body Mass Index of 18 to 35
Osteopenic
See 2 more
Treatment Details
Interventions
- DP001 (Vitamin D Analog)
Participant Groups
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Group 3Experimental Treatment1 Intervention
440 ng
Group II: Group 2Experimental Treatment1 Intervention
220 ng
Group III: Group 1Placebo Group1 Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Deltanoid Pharmaceuticals
Lead Sponsor
Trials
5
Recruited
580+